Skip to main content
SpringerLink
Log in

Blood d-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine

  • Letter to the Editor
  • Published:
Psychopharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Hashimoto K (2009) Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 61:105–123

    Article  PubMed  CAS  Google Scholar 

  • Hashimoto K (2014a) R-Stereoisomer of ketamine as alternative of ketamine for treatment-resistant major depression. Clin Psychopharmacol Neurosci 12:72–73

    Article  PubMed  PubMed Central  Google Scholar 

  • Hashimoto K (2014b) Targeting of NMDA receptors in the new treatment of schizophrenia. Expert Opin Ther Targets 18:1049–1063

  • Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M (2003) Decreased serum levels of d-serine in patients with schizophrenia. Evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60:572–576

    Article  PubMed  CAS  Google Scholar 

  • Hashimoto K, Malchow B, Falkai P, Schmitt A (2013) Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 263:367–377

    Article  PubMed  Google Scholar 

  • Hashimoto K, Sawa A, Iyo M (2007) Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62:1310–1316

    Article  PubMed  CAS  Google Scholar 

  • Hirabayashi Y, Furuya S (2008) Roles of l-serine and sphingolipid synthesis in brain development and neuronal survival. Prog Lipid Res 47:188–203

    Article  PubMed  CAS  Google Scholar 

  • Krystal JH, Sanacora G, Duman RS (2013) Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73:1133–1141

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Maekawa T, Ohnishi T, Hashimoto K, Watanabe A, Iwayama Y, Ohba H, Hattori E, Yamada K, Yoshikawa T (2010) Analyses of mechanism for mouse strain-dependent prepulse inhibition point to a role of Shmt1 (SHMT1) in mice and schizophrenia. J Neurochem 115:1374–1385

    Article  PubMed  CAS  Google Scholar 

  • Moaddel R, Luckenbaugh DA, Xie Y, Villasenor A, Brutsche NE, Machado-Vieira R, Ramamoorthy A, Lorenzo MP, Carcia A, Bernier M, Torjman MC, Barbas C, Zarate CA, Wainer JW (2014) d-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with major depressive disorder. Psychopharmacology in press

  • Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, Takao H, Toyota T, Minabe Y, Nakamura K, Shimizu E, Itokawa M, Mori N, Iyo M, Yoshikawa T (2005) Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and d-serine levels. Biol Psychiatry 57:1493–1503

    Article  PubMed  CAS  Google Scholar 

  • Yang C, Hashimoto K (2014) Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology 231:2041–2042

    Article  PubMed  CAS  Google Scholar 

  • Zarate CA Jr, Brutsche N, Laje G, Luckenbaugh DA, Venkata SLV, Ramamoorthy A, Moaddel R, Wainer IW (2012) Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 72:331–338

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Zhang JC, Li SX, Hashimoto K (2014) R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 116:137–141

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by a Grant-in-Aid for Scientific Research on Innovative Areas of the Ministry of Education, Culture, Sports, Science, and Technology, Japan (to K. H.).

Conflict of interest

Dr. Hashimoto is an inventor on a filed patent application (pending) on “d-Serine as a biomarker of schizophrenia” and “The use of R-ketamine in the treatment of psychiatric diseases.” Dr. Hashimoto has served as a scientific consultant to Astellas and Taisho, and he also received the research support from Abbvie, Dainippon Sumitomo, Mochida, Otsuka, and Taisho.

Author information

Authors and Affiliations

  1. Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba, 260-8670, Japan

    Kenji Hashimoto

Authors
  1. Kenji Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenji Hashimoto.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hashimoto, K. Blood d-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine. Psychopharmacology 231, 4081–4082 (2014). https://doi.org/10.1007/s00213-014-3735-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-014-3735-7

Keywords

Search

Navigation